MTOR and Buschke-Ollendorff syndrome: Comparison of three pharmaceuticals with potential activity in BOS revealed that azithromycin was a potent inhibitor of EMT in both SAEC and LAEC, while mycophenolate was a weaker inhibitor and the mTOR inhibitor, everolimus, had no effect.